OSIR Stock UPDATES Osiris Therapeutics (OSIR) 14.59 08/02/2014
Post# of 273250
Posted On: 08/02/2014 3:37:24 PM
Osiris Therapeutics (OSIR) 14.59 $OSIR
Grafix(R) Manuscript from Osiris' Multi-center, Randomized, Controlled Clinical Trial Available Electronically in Peer-Reviewed Journal
Business Wire - Tue Jul 22, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix(R) to control in patients with chronic diabetic foot ulcers (DFUs), which was accepted for publication in the International Wound Journal, is now available online and will also be in an upcoming issue.
Osiris Expands its Grafix(R) Product Portfolio and Launches Additional Sizes
Business Wire - Wed Jul 16, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced the addition of several new sizes to the Grafix(R) product line. Grafix, a cryopreserved placental membrane, is regulated under 21 CFR 1271, part 361, Human Cells, Tissues and Cellular Tissue-Products (HCT/Ps) as a wound cover. Like other HCT/Ps, Grafix can be manufactured in multiple sizes, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is now available in five convenient sizes and is very well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system.
Osiris Therapeutics Announces Second Quarter 2014 Financial Results Conference Call
Business Wire - Mon Jul 14, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for second quarter ended June 30, 2014, on Thursday, August 7, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Thursday, August 7, 2014, at 9:00 a.m. ET.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis
M2 - Fri Jul 11, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfm5cm/stem_cell_therapy) has announced the addition of the "Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis" report to their offering. The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market. In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012. Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth. Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Pipeline Analysis 5 Investor Network 6 Global Stem Cell Therapy Market, By Mode Of Therapy 7 Global Stem Cell Therapy Market, By Therapeutic Applications 8 Regulatory Landscape 9 Global Stem Cell Therapy Market, By Geography 10 Competitive Landscape 11 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/vf...ll_therapy
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:44AM CDT
BIND Therapeutics stock fell over 10% last trading session, reversing its recent trend
Advanced Wound Care Markets Worldwide
M2 - Thu Jun 26, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crcd5q/advanced_wound) has announced the addition of the "Advanced Wound Care Markets Worldwide" report to their offering. Advanced Wound Care Markets The wound care industry is an incredibly diverse and highly competitive arena that is ever-changing. Kalorama Information feels that the market will continue to expand over the long term due to an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings. This report, Advanced Wound Care Markets, provides breakouts of the market by category, including the following: - Skin Ulcers (Management, Moist Dressing, Negative Pressure Wound Therapy, Biological Dressings, Pressure Relief) - Burns Wound Care Market (Anti-Infectives, Management, Moist Dressing, Biological Dressings, Pressure Relief) - Surgical and Trauma Wounds (Wound Closure, Anti-Infectives, Moist Dressing, Biological Dressing, Miscellaneous Surgical and Trauma Wound Treatments) Wound Care Clinics The information and analysis presented in this report are based on extensive surveys of senior management in the wound care market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct over 100 face to face, telephone and email interviews with industry executives and product managers to validate and obtain expert opinion on current and future trends in the wound care industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections. - 3M Health Care - ABL Medical, LLC - ACELL, INC - Alliqua Biomedical, Inc - Amniox Medical - Angelini Pharma, Inc - Argentum Medical, LLC - ArjoHuntleigh - Arobella Medical, LLC - Baxter Bioscience - B. Braun/Aesculap, Inc. - BSN medical - Celleration - Coloplast A/S - ConvaTec, Ltd. - Covidien, Ltd - CryoLife, Inc. - Curaline, Inc - Derma Sciences - DeRoyal Industries - EHOB, Inc - Ethicon, Inc - GlaxoSmithKline Plc - Hartmann Group - Hill-Rom Company, Inc. - Hollister Wound Care LLC - Integra Life Sciences - Johnson & Johnson - Kinetic Concepts, Inc. (KCI) - LifeBond Ltd - Lohmann and Rauscher GmbH - Marine Polymer Technologies, Inc. - Medline Industries - MiMedx - Molnlycke HealthCare - MPM Medical, Inc - Oculus Innovative Sciences, Inc - Organogenesis, Inc - Osiris Therapeutics, Inc - Pfizer, Inc. - Shire Plc - Smith & Nephew, Plc - Soluble Systems, LLC - Southwest Technologies - Spiracur, Inc - SteadMed Medical - Stryker Corp For more information visit http://www.researchandmarkets.com/research/cr...nced_wound
Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating
M2 - Mon Jun 23, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5k8cfq/global_type_1) has announced the addition of the "Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating" report to their offering. The Global Type 1 Diabetes Market will grow at a CAGR of 6.9% over the period 2013-2018. One of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges. Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management. Key Vendors - Astrazeneca plc - Eli Lilly and Co. - Novo Nordisk A/S - Sanofi-Aventis US LLC Other Prominent Vendors - Biodel Inc. - Diamyd Medical AB - DiaVacs Inc. - Generex Biotechnology Corp. - Lexicon Pharmaceuticals Inc. - Macrogenics Inc. - MannKind Corp. - Osiris Therapeutics Inc. - Tolerion Inc. - XOMA Corp. For more information visit http://www.researchandmarkets.com/research/5k...bal_type_1
Merge Healthcare: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:55PM CDT
On Jun 20, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE).
Illumina: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:30PM CDT
On Jun 20, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Osiris Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Fri Jun 20, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 10:00 a.m. ET in New York City.
Grafix(R) Manuscript from Osiris' Multi-center, Randomized, Controlled Clinical Trial Accepted in Peer-Reviewed Journal
Business Wire - Thu Jun 19, 7:02AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix(R) to control in patients with chronic diabetic foot ulcers (DFUs) has been accepted for publication in the International Wound Journal. The peer-reviewed journal will report findings from Osiris' trial, Protocol 302, which demonstrated the overwhelming efficacy of Grafix compared to control in the closure of DFUs over 12 weeks (62% vs. 21.3%, p=0.0001, n=97). Entitled "The Efficacy and Safety of Grafix for the Treatment of Chronic Diabetic Foot Ulcers: Results of a Multicenter, Controlled, Randomized, Blinded, Clinical Trial", the publication will also highlight the trial's secondary endpoints - all of which showed statistically significant improvements for patients treated with Grafix compared to control. Grafix was not only favored in time to wound closure (42 days vs. 70 days, p=0.019), number of treatment applications (6 vs. 12, p=0.0001) and probability of wound closure by 12 weeks (67.1% vs. 27.1%, p<0.0001) but also in important safety endpoints including number of patients with adverse events (44% vs. 66%, p=0.031) and wound related infections (18% vs. 36.2%, p=0.044). The publisher expects the electronic publication to be available in July, with the hard copy to follow.
Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 12:10PM CDT
While the lifting of the partial clinical hold is a step in the right direction, the full clinical hold on Geron's (GERN) imetelstat is still in place.
Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 7:56AM CDT
Orexigen Therapeutics (OREX) fell nearly 15% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is up nearly 7% in the past one-month time frame.
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wd6llq/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Osiris Therapeutics, Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Rigel Pharmaceuticals, Inc. - Gentium S.p.A. - Immunomedics, Inc. - Mesoblast Limited - Swedish Orphan Biovitrum AB - Accentia Biopharmaceuticals, Inc. - Jazz Pharmaceuticals plc - Soligenix, Inc. - NeoStem, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. - Tobira Therapeutics, Inc. - REGiMMUNE Corporation - Adienne Pharma & Biotech - Nephrx Corporation - Dr. Falk Pharma GmbH - Lycera Corp. - Neopharm Ltd. - Pharmicell Co., Ltd. - Sigmoid Pharma Ltd. - Targazyme, Inc. - Kadmon Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/wd...ersus_host
Biogen's Eloctate Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 12:50PM CDT
The FDA approved Biogen's (BIIB) hemophilia A treatment, Eloctate, which will be launched in July.
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
M2 - Mon Jun 09, 5:15AM CDT
The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.
Osiris (OSIR): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:40AM CDT
Osiris witnessed solid estimate revisions and has an impressive Zacks Rank suggest that the company has potential for gains in future.
Gilead Unveils GS-9973 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:40AM CDT
Gilead (GILD) announced updated interim data on GS-9973 from an ongoing phase II study.
Grafix(R) Manuscript from Osiris' Multi-center, Randomized, Controlled Clinical Trial Available Electronically in Peer-Reviewed Journal
Business Wire - Tue Jul 22, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix(R) to control in patients with chronic diabetic foot ulcers (DFUs), which was accepted for publication in the International Wound Journal, is now available online and will also be in an upcoming issue.
Osiris Expands its Grafix(R) Product Portfolio and Launches Additional Sizes
Business Wire - Wed Jul 16, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced the addition of several new sizes to the Grafix(R) product line. Grafix, a cryopreserved placental membrane, is regulated under 21 CFR 1271, part 361, Human Cells, Tissues and Cellular Tissue-Products (HCT/Ps) as a wound cover. Like other HCT/Ps, Grafix can be manufactured in multiple sizes, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is now available in five convenient sizes and is very well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system.
Osiris Therapeutics Announces Second Quarter 2014 Financial Results Conference Call
Business Wire - Mon Jul 14, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for second quarter ended June 30, 2014, on Thursday, August 7, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Thursday, August 7, 2014, at 9:00 a.m. ET.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis
M2 - Fri Jul 11, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfm5cm/stem_cell_therapy) has announced the addition of the "Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis" report to their offering. The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market. In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012. Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth. Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Pipeline Analysis 5 Investor Network 6 Global Stem Cell Therapy Market, By Mode Of Therapy 7 Global Stem Cell Therapy Market, By Therapeutic Applications 8 Regulatory Landscape 9 Global Stem Cell Therapy Market, By Geography 10 Competitive Landscape 11 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/vf...ll_therapy
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:44AM CDT
BIND Therapeutics stock fell over 10% last trading session, reversing its recent trend
Advanced Wound Care Markets Worldwide
M2 - Thu Jun 26, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crcd5q/advanced_wound) has announced the addition of the "Advanced Wound Care Markets Worldwide" report to their offering. Advanced Wound Care Markets The wound care industry is an incredibly diverse and highly competitive arena that is ever-changing. Kalorama Information feels that the market will continue to expand over the long term due to an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings. This report, Advanced Wound Care Markets, provides breakouts of the market by category, including the following: - Skin Ulcers (Management, Moist Dressing, Negative Pressure Wound Therapy, Biological Dressings, Pressure Relief) - Burns Wound Care Market (Anti-Infectives, Management, Moist Dressing, Biological Dressings, Pressure Relief) - Surgical and Trauma Wounds (Wound Closure, Anti-Infectives, Moist Dressing, Biological Dressing, Miscellaneous Surgical and Trauma Wound Treatments) Wound Care Clinics The information and analysis presented in this report are based on extensive surveys of senior management in the wound care market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct over 100 face to face, telephone and email interviews with industry executives and product managers to validate and obtain expert opinion on current and future trends in the wound care industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections. - 3M Health Care - ABL Medical, LLC - ACELL, INC - Alliqua Biomedical, Inc - Amniox Medical - Angelini Pharma, Inc - Argentum Medical, LLC - ArjoHuntleigh - Arobella Medical, LLC - Baxter Bioscience - B. Braun/Aesculap, Inc. - BSN medical - Celleration - Coloplast A/S - ConvaTec, Ltd. - Covidien, Ltd - CryoLife, Inc. - Curaline, Inc - Derma Sciences - DeRoyal Industries - EHOB, Inc - Ethicon, Inc - GlaxoSmithKline Plc - Hartmann Group - Hill-Rom Company, Inc. - Hollister Wound Care LLC - Integra Life Sciences - Johnson & Johnson - Kinetic Concepts, Inc. (KCI) - LifeBond Ltd - Lohmann and Rauscher GmbH - Marine Polymer Technologies, Inc. - Medline Industries - MiMedx - Molnlycke HealthCare - MPM Medical, Inc - Oculus Innovative Sciences, Inc - Organogenesis, Inc - Osiris Therapeutics, Inc - Pfizer, Inc. - Shire Plc - Smith & Nephew, Plc - Soluble Systems, LLC - Southwest Technologies - Spiracur, Inc - SteadMed Medical - Stryker Corp For more information visit http://www.researchandmarkets.com/research/cr...nced_wound
Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating
M2 - Mon Jun 23, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5k8cfq/global_type_1) has announced the addition of the "Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating" report to their offering. The Global Type 1 Diabetes Market will grow at a CAGR of 6.9% over the period 2013-2018. One of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges. Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management. Key Vendors - Astrazeneca plc - Eli Lilly and Co. - Novo Nordisk A/S - Sanofi-Aventis US LLC Other Prominent Vendors - Biodel Inc. - Diamyd Medical AB - DiaVacs Inc. - Generex Biotechnology Corp. - Lexicon Pharmaceuticals Inc. - Macrogenics Inc. - MannKind Corp. - Osiris Therapeutics Inc. - Tolerion Inc. - XOMA Corp. For more information visit http://www.researchandmarkets.com/research/5k...bal_type_1
Merge Healthcare: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:55PM CDT
On Jun 20, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE).
Illumina: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:30PM CDT
On Jun 20, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Osiris Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Fri Jun 20, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 10:00 a.m. ET in New York City.
Grafix(R) Manuscript from Osiris' Multi-center, Randomized, Controlled Clinical Trial Accepted in Peer-Reviewed Journal
Business Wire - Thu Jun 19, 7:02AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix(R) to control in patients with chronic diabetic foot ulcers (DFUs) has been accepted for publication in the International Wound Journal. The peer-reviewed journal will report findings from Osiris' trial, Protocol 302, which demonstrated the overwhelming efficacy of Grafix compared to control in the closure of DFUs over 12 weeks (62% vs. 21.3%, p=0.0001, n=97). Entitled "The Efficacy and Safety of Grafix for the Treatment of Chronic Diabetic Foot Ulcers: Results of a Multicenter, Controlled, Randomized, Blinded, Clinical Trial", the publication will also highlight the trial's secondary endpoints - all of which showed statistically significant improvements for patients treated with Grafix compared to control. Grafix was not only favored in time to wound closure (42 days vs. 70 days, p=0.019), number of treatment applications (6 vs. 12, p=0.0001) and probability of wound closure by 12 weeks (67.1% vs. 27.1%, p<0.0001) but also in important safety endpoints including number of patients with adverse events (44% vs. 66%, p=0.031) and wound related infections (18% vs. 36.2%, p=0.044). The publisher expects the electronic publication to be available in July, with the hard copy to follow.
Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 12:10PM CDT
While the lifting of the partial clinical hold is a step in the right direction, the full clinical hold on Geron's (GERN) imetelstat is still in place.
Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 7:56AM CDT
Orexigen Therapeutics (OREX) fell nearly 15% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is up nearly 7% in the past one-month time frame.
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wd6llq/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Osiris Therapeutics, Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Rigel Pharmaceuticals, Inc. - Gentium S.p.A. - Immunomedics, Inc. - Mesoblast Limited - Swedish Orphan Biovitrum AB - Accentia Biopharmaceuticals, Inc. - Jazz Pharmaceuticals plc - Soligenix, Inc. - NeoStem, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. - Tobira Therapeutics, Inc. - REGiMMUNE Corporation - Adienne Pharma & Biotech - Nephrx Corporation - Dr. Falk Pharma GmbH - Lycera Corp. - Neopharm Ltd. - Pharmicell Co., Ltd. - Sigmoid Pharma Ltd. - Targazyme, Inc. - Kadmon Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/wd...ersus_host
Biogen's Eloctate Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 12:50PM CDT
The FDA approved Biogen's (BIIB) hemophilia A treatment, Eloctate, which will be launched in July.
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
M2 - Mon Jun 09, 5:15AM CDT
The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.
Osiris (OSIR): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:40AM CDT
Osiris witnessed solid estimate revisions and has an impressive Zacks Rank suggest that the company has potential for gains in future.
Gilead Unveils GS-9973 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:40AM CDT
Gilead (GILD) announced updated interim data on GS-9973 from an ongoing phase II study.
(0)
(0)Scroll down for more posts ▼